Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
October 5, 2026 5:24 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $150.00 price target on Kymera Therapeutics (NASDAQ: KYMR)
Opens 90-Day Upside Catalyst Watch.For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.
Shares of Kymera Therapeutics closed at $107.39 yesterday.
... More


